文献速递糖尿病

SGLT2抑制剂在2型糖尿病心衰一级预防中的精准处方:模型开发与验证

Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study.
PubMed 文献 · Diabetes Care · 2026-01-01

本研究开发并验证了SABRE模型,用于预测无ASCVD、心衰或CKD的2型糖尿病患者使用SGLT2i的个体化5年心衰绝对获益。模型结合QDiabetes-HF模型的绝对心衰风险与试验荟萃分析的HR 0.63,在英国初级保健数据中验证。SGLT2i使用与心衰风险降低30%相关(HR 0.70,95%CI 0.63-0.78),相对获益不随基线绝对风险变化(P=0.82),SABRE预测的5年绝对获益范围为<0.1%至14.1%,校准良好且比现行指南更具针对性。

要点

  • SABRE模型可估算无ASCVD、心衰或CKD的T2D患者使用SGLT2i的5年心衰绝对获益。
  • SGLT2i相对心衰获益不随基线绝对风险变化,支持按绝对风险选择患者。
  • SABRE模型预测的5年绝对获益中位数为1.0%,范围<0.1%至14.1%。

核心结论

  • SABRE模型整合试验证据,可易部署地精准定位T2D患者中SGLT2i用于心衰一级预防的个体化获益。

研究设计与样本

  • 开发SABRE模型,结合QDiabetes-HF模型的绝对心衰风险与SGLT2i相关心衰住院HR 0.63(来自试验荟萃分析)估算个体5年心衰获益。
  • 使用2013至2020年英国初级保健数据(链接医院和死亡记录)验证模型组件和预测,包括57,368名SGLT2i起始者和111,673名对照(DPP-4i或磺脲类)起始者。

主要发现

  • SGLT2i使用与新生心衰风险降低30%相关(HR 0.70,95%CI 0.63-0.78),与试验证据一致。
  • 相对心衰获益不随基线绝对心衰风险变化(P=0.82)。
  • SABRE模型预测的5年绝对心衰获益范围为<0.1%至14.1%,中位数1.0%(四分位距0.6-1.8%),对观察心衰结局校准良好。
  • 在无ASCVD、心衰或CKD的T2D患者中,SABRE比现行指南提供更针对性的心衰预防。

关键数值与推荐

  • SGLT2i相关心衰住院的HR为0.63(来自试验荟萃分析),用于SABRE模型估算个体5年绝对获益。
  • SGLT2i使用与新生心衰风险的HR为0.70(95%CI 0.63-0.78),相对获益不随基线绝对风险变化(P=0.82)。
  • SABRE预测的5年绝对心衰获益范围<0.1%至14.1%,中位数1.0%(IQR 0.6-1.8%)。

临床怎么用

  • 对于无ASCVD、心衰或CKD的T2D患者,可使用SABRE模型评估个体5年心衰绝对获益以指导SGLT2i精准处方。
  • SGLT2i的相对获益在不同基线风险患者中一致,选择患者应基于绝对风险而非相对获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce heart failure (HF) risk in type 2 diabetes (T2D) and are recommended for patients with T2D who have atherosclerotic cardiovascular disease (ASCVD), HF, or chronic kidney disease (CKD). However, most individuals with T2D do not have these conditions, and current guidelines for this group do not indicate which individuals may benefit most from SGLT2i. We aimed to develop and validate a model to predict the individual-level HF benefit of SGLT2i in individuals with T2D without ASCVD, HF, or CKD. RESEARCH DESIGN AND METHODS: We developed the SGLT2i Absolute Benefit Response (SABRE) model, combining absolute HF risk from the validated QDiabetes-HF model with the SGLT2i-associated hazard ratio (HR) for HF hospitalization from a trial meta-analysis (HR 0.63) to estimate individual 5-year HF benefit. Model components and predictions were validated using U.K. primary care data with linked hospital and death records from 2013 to 2020. RESULTS: Among 57,368 SGLT2i initiators and 111,673 comparator (dipeptidyl peptidase 4 inhibitor or sulfonylurea) initiators, SGLT2i use was associated with a 30% lower risk of new-onset HF (HR 0.70 [95% CI 0.63-0.78]), consistent with trial evidence. Relative HF benefit did not vary by baseline absolute HF risk (P = 0.82). The SABRE model-predicted 5-year absolute HF benefit with SGLT2i ranged from <0.1% to 14.1% (median 1.0% [interquartile range 0.6-1.8%]) and calibrated well against observed HF outcomes. SABRE provided more targeted HF prevention than current guidelines in those with T2D without ASCVD, HF, or CKD. CONCLUSIONS: The SABRE model is an easily deployed clinical prediction model integrating trial evidence and allowing more precise targeting of SGLT2i for primary HF prevention in T2D.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Young KG, McGovern AP, Hopkins R, et al. Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study. Diabetes Care. 2026. PMID: 42160591. doi:10.2337/dc25-2973

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。